Seikagaku has instituted a mid-term management plan covering the four-year period beginning with the fiscal year ending March 31, 2023, positioned as a period for achieving growth, and is implementing five key measures set out in the management plan.

 

An important element of the mid-term management plan is regulatory approval in the U.S. and market introduction of SI-6603, a treatment for lumbar disc herniation. We believe that introducing SI-6603 in the U.S. to provide a new treatment option for patients will result in a growth driver for Seikagaku. A Biologics License Application (BLA) has been accepted for filing by the U.S. Food and Drug Administration (FDA), which means that SI-6603 is now a step away from release in the U.S. market.

 

Also, with a view to future business development, we are proceeding with production optimization from a global perspective. For instance, we are aggressively investing in facilities and reinforcing human resources to enable Canadian subsidiary Dalton Chemical Laboratories, Inc. to manufacture certain Seikagaku products, including new products. Through these initiatives, we aim to achieve record-high business results in the final year of the management plan.        

 

Seikagaku also regards sustainability initiatives as an important priority. As a measure to reduce environmental impacts, we have procured CO₂-free electricity and achieved conversion to non-fossil energy at business sites in Japan. These and other environmental initiatives have been recognized by external assessment organizations, and Seikagaku has been awarded a Silver sustainability rating by EcoVadis and a CDP climate change assessment score of B for 2023.

 

I request the continued understanding and support of our shareholders and other stakeholders.

December 2024
 Ken Mizutani
 President & CEO